Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Awakn Life Sciences Corp C.AWKN

Alternate Symbol(s):  AWKNF

Healthcare Psychedelics
Awakn Life Sciences Corp. is a Canada-based clinical-stage biotechnology company. The Company is developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company... see more

Recent & Breaking News (CSE:AWKN)

Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic

Newsfile April 3, 2024

Canadian Securities Exchange Reports February 2024 Performance Figures

Newsfile March 15, 2024

Canadian Securities Exchange Welcomes Listing of Awakn Life Sciences Corp

Newsfile February 13, 2024

Awakn Life Sciences Announces Listing on the Canadian Securities Exchange

Newsfile February 12, 2024

Awakn Life Sciences Announces Conditional Approval of CSE Listing

Newsfile February 5, 2024

Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers

Newsfile January 24, 2024

Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS

Newsfile December 20, 2023

Awakn Life Sciences Provides Corporate Update

Newsfile December 15, 2023

Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001

Newsfile November 15, 2023

Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements

Newsfile November 10, 2023

Awakn Life Sciences Engages Orphan Insight Ltd. to Advance Market Access, Pricing, and Reimbursement Strategies for AWKN-P001 Targeting Severe Alcohol Use Disorder

Newsfile October 31, 2023

Awakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study

Newsfile October 4, 2023

Awakn Life Sciences Provides Corporate Update

Newsfile September 14, 2023

Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001

Newsfile September 6, 2023

Awakn Life Sciences Completes Sale of Awakn Clinics In Norway

Newsfile August 1, 2023

Awakn Life Sciences Completes Sale of Awakn Clinics London

Newsfile July 5, 2023

Awakn Life Sciences Announces Results of Annual General and Special Meeting

Newsfile June 27, 2023

Awakn Life Sciences to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC

Newsfile June 19, 2023

Awakn Life Sciences Announces Closing of the Second Tranche and Upsizing of Previously Announced Private Placement

Newsfile June 15, 2023

Canadian Investment Regulatory Organization Trade Resumption - AWKN

Canada NewsWire June 9, 2023